Key Highlights

  • JBIO reported a Q3 net loss of US$35,055 thousand, or US$0.42 per share.
  • Research and development expenses were US$30,823 thousand versus US$22,010 thousand.
  • Cash, cash equivalents and investments were US$475.7 million at September 30, 2026.
  • JUNIPER Phase 2 trial of JADE101 dosed its first patient in May 2026.

JBIO filed its Quarterly Report on November 13, 2026, for the three and nine months ended September 30, 2026. Research and Development expenses were US$30,823 thousand, versus US$22,010 thousand. General and administrative expenses were US$8,817 thousand, versus US$5,391 thousand. Total operating expenses were US$39,640 thousand versus US$27,401 thousand, and the loss from operations equaled those amounts.

Interest income was US$4,629 thousand versus US$2,254 thousand. Net loss was US$(35,055) thousand, versus US$(25,175) thousand, or US$(0.42) per common share versus US$(0.48). Weighted average shares were 71,763,164 versus 39,584,489.

Program Spending and Nine-Month Results

External JADE101 costs were US$12,056 thousand versus US$6,035 thousand, including US$5.8 million for chemistry, Manufacturing and controls and US$4.5 million for early-stage clinical trial costs. JADE201 costs were US$3,516 thousand versus US$6,720 thousand, and JADE301 costs were US$2,638 thousand versus US$1,605 thousand. Personnel-related costs, including stock-based compensation, were US$10,012 thousand versus US$7,060 thousand, and other research costs were US$2,601 thousand versus US$590 thousand.

For the nine months, research and development expenses were US$116,941 thousand versus US$64,580 thousand, and general and administrative expenses were US$25,060 thousand versus US$13,983 thousand. Net loss was US$(131,188) thousand, or US$(1.72) per share, versus US$(95,478) thousand, or US$(3.08). The prior-year period included a US$21,584 thousand change in Fair Value of convertible notes.

Equity Financing, Liquidity and Clinical Programs

The company reported cash, cash equivalents and investments of US$475.7 million at September 30. It said it has funded operations with US$95.0 million of gross proceeds from convertible notes, US$557.5 million of gross proceeds from equity financings and US$75.3 million of gross sales through its at-the-market program. On June 5, 2026, it completed an underwritten offering of 11,500,000 shares at US$15.00 per share for gross proceeds of US$172.5 million. In the nine months it sold 3,499,302 shares under the at-the-market program for gross proceeds of US$75.3 million, less US$1.5 million of issuance costs.

JADE101 is an anti-APRIL antibody being developed for IgA nephropathy. The company said its Phase 1 trial in 32 healthy volunteers evaluated single subcutaneous doses of 175 mg to 1,400 mg, and that in June 2026 it reported IgA reductions of approximately 70% from baseline sustained at 12 weeks at the 700 mg dose. It said the JUNIPER Phase 2 trial, with about 30 participants, dosed its first patient in May 2026, with interim clinical data expected in the second quarter of 2027, and that it has a Phase 3 trial, EVERGREEN, planned.

Quarter in Review: Three Programs and Funding Sources

JBIO's third quarter combined higher research and administrative spending and a net loss of US$35,055 thousand with a cash and investments balance of US$475.7 million. The company described three programs: JADE101 targeting APRIL, JADE201 targeting BAFF-R, and JADE301 targeting interferon beta, initially for dermatomyositis. It also reported an October 2025 private Placement of approximately US$135 million, with net proceeds of approximately US$126.4 million.